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Abstract
Background—Sleep-disordered-breathing (SDB), which is characterized by chronic intermittent
hypoxia (IH) and sleep fragmentation (SF), is a prevalent condition that promotes metabolic
dysfunction, particularly among patients suffering from obstructive hypoventilation syndrome
(OHS). Exosomes are generated ubiquitously, are readily present in the circulation, and their cargo
may exert substantial functional cellular alterations in both physiological and pathological
conditions. However, the effects of plasma exosomes on adipocyte metabolism in patients with
OHS or in mice subjected to IH or SF mimicking SDB are unclear.
Methods—Exosomes from fasting morning plasma samples from obese adults with
polysomnographically-confirmed OSA before and after 3 months of adherent CPAP therapy were
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assayed. In addition, C57BL/6 mice were randomly assigned to (1) sleep control (SC), (2) sleep
fragmentation (SF), and (3) intermittent hypoxia (HI) for 6 weeks, and plasma exosomes were
isolated. Equivalent exosome amounts were added to differentiated adipocytes in culture, after
which insulin sensitivity was assessed using 0 nM and 5nM insulin-induced pAKT/AKT
expression changes by western blotting.
Results—When plasma exosomes were co-cultured and internalized by human naïve adipocytes,
significant reductions emerged in Akt phosphorylation responses to insulin when compared to
exosomes obtained after 24 months of adherent CPAP treatment (n=24; p<0.001), while no such
changes occur in untreated patients (n=8). In addition, OHS exosomes induced significant
increases in adipocyte lipolysis that were attenuated after CPAP, but did not alter pre-adipocyte
differentiation. Similarly, exosomes from SF- and IH-exposed mice induced attenuated p-AKT/
total AKT responses to exogenous insulin and increased glycerol content in naïve murine
adipocytes, without altering pre-adipocyte differentiation.
Conclusions—Using in vitro adipocyte-based functional reporter assays, alterations in plasma
exosomal cargo occur in SDB, and appear to contribute to adipocyte metabolic dysfunction.
Further exploration of exosomal miRNA signatures in either human subjects or animal models and
their putative organ and cell targets appears warranted.
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INTRODUCTION
Obesity is a major risk factor for the development of metabolic syndrome and insulin
resistance, and is associated with an increased risk of disability and morbidity 1, 2. One of
the consequences of morbid obesity is the obesity hypoventilation syndrome (OHS), which
is characterized by a combination of obesity and chronic hypoventilation along with
increased early mortality 3–5. It is estimated that 90% of patients with OHS also have
obstructive sleep apnea (OSA) 6. The exact prevalence of OHS in the community is unclear,
but is estimated to be approximately 0.15–0.6% of the general population 7, 8, 9–20% of
referred obese patients, and up to 42% of referrals when BMI is >35 kg/m2 9–11. In addition,
a paradoxical protective effect of OHS on cardiovascular function has been recently
suggested 12, such that it is yet unclear how OHS and OSA in obese patients differ as far as
their potential contributions to end-organ morbidity. Previous studies have also
demonstrated that treatment with continuous positive airway pressure (CPAP) or
noninvasive ventilation (NIV) in patients with OHS and OSA is beneficial, while
supplemental oxygen alone does not appear to be of clinical value 13, 14.
Although metabolic dysfunction is now clearly associated with OSA, the impact of OHS on
insulin resistance and dyslipidemia is still virtually unexplored 15, 16. Indeed, there have
been few if any longitudinal studies evaluating the metabolic changes resulting from OHS
treatment 17, and the exact molecular mechanisms of OHS-associated insulin resistance are
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unclear. Identification of biomarkers indicating which OHS patients are at greater metabolic
risk would be extremely useful. In this setting, extracellular vesicles (EVs) or EV-associated
molecules are emerging as promising biomarkers in insulin resistance, diabetes, and the
metabolic syndrome 18–22. Therefore, identifying and characterizing pathways leading to
insulin resistance would help in designing strategies to treat this problem.
Exosomes are very small vesicles (30–120 nm) that are present in many and perhaps all
biological fluids 23–27, where they participate in a vast array of physiological processes such
as cell metabolism, proliferation and differentiation 28, 29. Plasma-derived exosomes can
interact with target tissues and disrupt or coordinate the enrollment of inflammatory cells
such as to alter adipocyte metabolic pathways, thereby promoting the development of insulin
resistance 21, 22, 30–32. Based on aforementioned considerations, we hypothesized that
plasma exosomes in OHS contribute to adipose tissue insulin resistance, and that such
effects will improve with treatment over time. To examine this issue, we took advantage of
the Pickwick’s Spanish Sleep Network Study 17, and assessed the in vitro effects of plasma
exosomes from OHS patients before and following up to 2 years of adherent CPAP
treatment on insulin sensitivity and adipocyte biology in naïve human adipocytes. To further
understand the potential contributions of chronic intermittent hypoxia (IH) and sleep
fragmentation (SF) to circulating exosomes and their putative functional alterations, we
conducted parallel and similar studies in mice (please, see Fig. S1).
MATERIALS AND METHODS
Human Subjects
The human subjects were recruited as part of a larger multicenter, randomized, controlled
trial conducted in 14 Spanish teaching hospitals (NCT01405976), and patient characteristics
have been described in detail elsewhere 17. Every patient underwent a diagnostic sleep
study. Patients allocated to CPAP underwent a titration study on a second night. CPAP
titration was performed using either conventional polysomnography or an automatic CPAP
following a validated protocol 33. The subjects were evaluated at diagnosis (Pre), and after
2, 12, and 24 months after initiation of CPAP treatment (T-2, T-12, and T-24M). Adherence
was defined at nightly use for at least 5.3 ± 2.1h/night throughout the duration of the study.
As controls, subjects who were diagnosed with OSA in the context of an ongoing parallel
study, the EPIOSA study (NCT02131610), but who opted for not receiving treatment for 12
months were also included 34.
Murine Models of OSA
All experiments were approved by The University of Chicago Institutional Animal Care and
Use Committee (IACUC protocols # 72078 and 72043). Mouse cages were randomly
assigned to sleep control (CTL), sleep fragmentation (SF), room air (RA) or intermittent
hypoxia (IH) conditions for periods of 1 day, 1, 2, 6 and 20 weeks.
Sleep Fragmentation (SF) and Intermittent Hypoxia (IH) (Online Supplement)
The paradigms used to induce SF and IH have been previously described 35–38.
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Measurements of Metabolic Parameters
Fasting blood samples were drawn after the sleep study, and immediately centrifuged,
aliquoted and stored at −80°C. Insulin concentrations were measured using ELISA kits
(ALPCO Diagnostics, Salem, NH). Insulin resistance was assessed using the homeostasis
model assessment (HOMA) equation (fasting insulin x fasting glucose/ 22.5) 39. Plasma
levels of adiponectin were measured using commercial assay kits (BioVison Inc., Milpitas,
CA), and human retinol-binding protein 4 (RBP4) was also measured using a Quantikine
ELISA Kit (R&D Systems, Inc., Minneapolis, MN).
Circulating Plasma Exosome Isolation and Quantification
Exosomes were isolated from frozen plasma using the Total Exosome Isolation Kit
according to the manufacturer’s protocol (Life Technologies, Grand Island, NY), as
previously described 25, 40, 41, and all necessary steps were undertaken to characterize the
purity of the exosomes as recommended (see below) 42.
The numbers of exosomes derived from human or mice samples were determined using the
Exocet kit (System Biosciences), according to the manufacturer’s protocols. The exosomes
were lysed using a gentle lysis buffer as to maintain the enzymatic activity of the exosomal
Acetylcholinesterase (AChE) enzyme. A standard curve was performed using known
numbers of exosomes (as measured by NanoSight) and calibrated with a recombinant AChE
enzyme standard solution provided in the kit. The enzyme activities of the samples and the
standards were determined by incubation in a reaction buffer in 96-well plates at room
temperature for 25 mins. The optical density was measured at 406 nm by a
spectrophotometric plate reader. The average of exosomes in human was 7.0–7.4x107/μl,
while for mice were 5.9–6.2 x107/μl. Equal exosomes numbers were used for each
experiment conditions.
Flow Cytometry
Different exosome surface markers were selected based on their functions including: (a)
tetraspanins (CD9, CD63 and CD81), (b) targeting/adhesion (CD 31), (c) antigen
presentation (HALA-G), and (d) membrane transport and fusion (Rab5a) that were bound to
Exo-Flow FACS magnetic beads [(9.1μm), (SBI, System Bioscience, Mountain View, CA)].
Labeled exosomes markers were analyzed on a FACSCanto II (FACSCalibur) flow
cytometer (BD Biosciences, San Jose, CA) using the FACSDiva software 2.56 (BD
Biosciences).
Exosome Cellular Uptake
Purified exosomes from either human or mouse plasma samples were labeled with green
fluorescent linker PKH67 (Sigma-Aldrich, St. Louis, MO), Exo-Red, and Exo-Green
(System Biosciences, Mountain View, CA), and further incubated at 37°C for 10 min, until
the reaction was stopped by adding ExoQuick-TC reagent. Labeled exosomes were added to
either differentiated human adipocytes (# PT-5006, Lonza, Walkersville, MD) or murine
3T3-L1 cells (ATCC, Manassas, VA) for 4 hours in a cell culture incubator at 37°C. Labeled
exosomes were monitored for delivery into target cells using a Leica SP5 Tandem Scanner
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Spectral 2-photon confocal microscope (Leica Microsystems, Inc., Buffalo Grove, IL) with a
63× oil-immersion lens.
Cell Cultures
Human Adipocytes—Human adipocytes [adipose derived stem cells, ADSCs] were
purchased from Lonza (# PT-5006, Lonza, Walkersville, MD) and cultured at 37°C, 5%
CO2, 95% relative humidity in pre-adipocyte basal media (PT-8202, Lonza) supplemented
with 10% fetal bovine serum, FBS, (Life Technologies, Carlsbad, CA). Cells were seeded in
24-well plates with 40,000 cells per well in basal medium PGM-2 (Lonza), and after 48 h,
cells were differentiated by changing to Bulletkit PGM-2 (PT-9502 & PT-8202) media
containing 10% FBS, 1 μg/ml insulin, 1 μM dexamethasone (DEX), and 0.5 mM 3-
isobutyl-1-methylxanthine. The medium was changed every 2 days for 12 days.
Murine Adipocytes—Mouse 3T3-L1 cells were purchased from ATCC (Manassas, VA).
The cells were maintained in DMEM (Life Technologies, Grand Island, NY) supplemented
with 10% (v/v) fetal calf serum, FCS, (Life Technologies), 100 U/mL penicillin, and 0.1
mg/mL streptomycin in incubator at 37°C. Day 0 was designated as the second day after the
confluence of the 3T3-L1 cells. To induce differentiation, pre-adipocytes were treated for 4
days beginning on D0 with 0.5 mmol/L, isobutylmethylxanthine, 2.5 mmol/L
dexamethasone and 8.7 mmol/L insulin in DMEM containing 10% fetal calf serum, F (Life
Technologies). The cells were subsequently replenished with DMEM containing 10% FCS
every other day.
Human and Mouse Plasma Exosomes and Pre-Adipocyte Proliferation and
Differentiation—Human ADSCs cells (4 x104 cells/well) or mice 3T3-L1 cells (4 x104
cells/well) were cultured in 24-well plates. Exosomes from human plasma were added to
ADSCs cells, and plasma exosomes from mice were added to mice 3T3-L1 cells for 3
consecutive days during proliferation. Medium was removed from the plates 24 h after
adding the last exosome administration, and the monolayers were rinsed with cold PBS and
200μl of CyQUANT GR dye/cell lysis buffer (included in the CyQUANT kit, Invitrogen,
Eugene, OR, USA) was added to each well. The fluorescence was measured using a
microplate reader. The excitation maximum was 485 nm, and the emission maximum was
530 nm.
For differentiation assays, equivalent numbers of exosomes were added every day to the
cells in the differentiation media for 3 consecutive days during the differentiation process for
3T3-L1, and every other day for human ADSCs cells. The differentiated human ADSCs or
3T3-L1 were fixed in 4% paraformaldehyde for 15 min. Isopropanol (60%) was then added
in each well, and cells were then stained using 0.5% Oil Red O solution diluted (60:40, v/v)
in isopropanol for 15 min at room temperature. The amount of intracellular lipid was
assessed by isopropanol dissolution and optical density measurement at 490 nm.
Effects of Exosomes on Insulin Sensitivity in Naïve Adipocytes—Human pre-
adipocytes or murine 3T3-L1 cells (4 x104 cells/well) were grown in 24-well plates, and
cells were differentiated as described above. By day of 12 of differentiation, media were
Khalyfa et al. Page 5













replaced by growth media containing 10% depleted FBS. Exosomes were added for 24
hours and adipocytes cells were treated with 0 or 5nm insulin (Sigma-Aldrich, St. Louis,
MO) at 37°C for 30min prior to lysis. Protein concentrations of the cell lysates were
determined using the BCA Kit (Life Technologies, Grand Island, NY). The lysates were
separated on 12% SDS-acrylamide gel and transferred to nitrocellulose membranes,
incubated in blocking buffer (5% nonfat dry milk in TBST) followed by phosphoAkt
(Ser473) antibody (Cell Signaling Technology, Danvers, MA) or Akt antibody (Cell
Signaling Technology) overnight at 4°C. Immune-reactive bands were visualized using an
enhanced chemiluminescence detection system (Chemidoc XRS+; Bio-Rad, Hercules, CA),
and quantified by the Image Lab software (Bio-Rad, Hercules, CA).
Effects of Exosomes on Lipolysis—Human adipocytes or murine adipocytes cells
were grown and differentiated in a 24-well cell culture plate. Cells were washed twice with
100 μl of Lipolysis Wash Buffer (# K622, Lonza, Walkersville, MD). As a positive control,
1.5 μl of 10 μM Isoproterenol (final concentration 100 nM) was added to 6-wells to
stimulate lipolysis for 3 hrs. Fifty μl of the media were into 96-well plate. Glycerol released
was measured by reading the absorbance (OD 570 nm) in a microtiter plate reader. Cells
were also lysed and used to normalize glycerol to cellular protein content using BCA Protein
Quantitation Kit (Cat. # K812).
Statistical Analysis
Data are reported as mean ± standard deviation. Comparisons between groups used unpaired
Student t-test, or a non-parametric equivalent when data were not normally distributed.
Comparisons between multiple groups used one-way analysis of variance (ANOVA) or
Two-tailed P values that were calculated for all pairwise multiple comparison procedures




A total of 24 subjects with OHS (12 M and 12 F) among those who were adherent to CPAP
for the complete duration of the trial were randomly selected from the database and their
samples were de-identified and transferred for analyses (see reference #13 for more details
on the clinical characteristics of the cohort). Mean age of male OHS subjects was 60.8
± 12.1 years, BMI was 43.8 ± 6.0 kg/m2 and AHI 57.2 ± 32.2/hr, while female OHS subjects
were 60.5 ± 15.5 year-old, with a mean BMI of 43.3 ± 5.3 kg/m2 and AHI 62.06 ± 27.7/h.
Although, there were no observed clinical improvements following two months of CPAP
therapy except for reductions in fasting insulin and HOMA-IR among OHS subjects, follow-
up assessments at 12 and 24 months of adherent CPAP therapy revealed significant
improvements in all metabolic parameters including increases in adiponectin concentrations,
as well as reductions in RBP4 levels in both men and women, with no detectable differences
among genders. In comparison, untreated subjects with OSA matched for age and gender
showed no improvements in any of the metabolic parameters after 12 months (Table 1).
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Exosome Characterization and Cellular Uptake
Flow cytometry of isolated exosomes derived from human OHS, OSA, or from murine
models of OSA revealed the presence of tetraspanins, targeting/adhesion, and antigen
presentation markers as anticipated from highly purified (>95%) exosome fractions (Figs.
S2 and S3). Exosomes derived from human plasma or murine plasma were incorporated into
either human or murine naïve differentiated adipocytes as shown in Fig. 1 and Fig. S4,
respectively, whereas no signal was observed in cells grown in medium supplemented
without exosomes to which PKH67 was also added (Fig. 1A & Fig. S4A). Of note, labeled
intracellular RNAs (Exo-Red) and intracellular proteins (Exo-Green) (Fig. 1B and C), were
not detectable in cells exposed to control media without exosomes (Figs. 1A– 1C; Fig. S4A–
S4C). In addition, analysis of exosome uptake performed in the differentiated adipocyte cell
lines by time-lapsed confocal microscopy revealed increasing uptake of labeled exosomes
over time. In this setting, cells exhibiting exosome uptake showed that both RNA and
protein co-localized with DAPI in the nucleus, while lipid localization was restricted to the
cell membrane. Exosome uptake was also dose-dependent, as there were increased spot
numbers, total fluorescence, and median pixel intensities of the dyes with increasing
exosome concentrations (data not shown).
Effects of Exosomes on Naïve Adipocytes
Insulin-induced pAkt level increases were markedly attenuated in adipocytes by exosomes
derived from patients with OHS prior to treatment and OSA indicating the presence of
insulin resistance, and significant increases in pAKT expression emerged following CPAP
treatment at all time points and no gender differences were detectable (Fig. 2A; pAkt/Akt
ratio for Pre-: 1.82±0.72 vs. Post-T-24M: 3.01±1.11, n=24, P<0.008). Similarly, mean
pAkt/Akt ratio for untreated OSA subjects did not change over a period of 12 months (Pre-:
1.31±0.25 vs. T-12M: 1.30±0.15, n=8, P=0.95).
Mice exposed to IH or SF develops evidence of insulin resistance 38, 43–46. Here, we used
plasma exosomes derived from mice exposed to SF or IH from 1 day-20 weeks to expose
naïve murine differentiated adipocytes (Fig. 2B & 2C). Exosomes from SF or IH induced
significant reductions in Akt phosphorylation responses to exogenous insulin after 6 and 20
weeks of exposure, while earlier time points did not exhibit significant alterations.
Effects of Exosomes on Pre-Adipocyte Proliferation and Differentiation
No significant differences in pre-adipocyte proliferation were detected at any of the time
points (Fig. 2A). Similarly, exosomes from mice exposed to SF or IH for short-term, mid-
term or long-term exposures had no discernible effects on adipocyte proliferation (Fig. 3B &
3C).
However, plasma exosomes derived from OHS subjects at baseline induced increased
adipocyte lipid accumulation, an indicator of pre-adipocyte differentiation, when compared
to all treatment time points, while no changes occurred in untreated OSA subjects (Fig. 4A).
Moreover, plasma exosomes from either SF or IH increased adipocyte lipid accumulation
when compared to their time-matched control groups, but only following mid-term and
long-time exposures (Fig. 4B & 4C).
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Effects of Exosomes on Lipolysis
Assessment of lipolysis after exosome treatment of human adipocytes revealed increased
glycerol release in Pre-treatment conditions, with significant reductions in lipolysis after
CPAP treatment at all time points (Fig. 5A). No significant differences in exosome-induced
lipolysis occurred in untreated subjects with sleep apnea (Fig. 5A). Notably, exosomes
derived from SF or IH mice also increased lipolysis as shown by glycerol release assay (Fig.
5A & 5C). In SF- or IH-exposed mice, the lipolysis induced by exosomes was increased
after mid-term and long-time exposures, but not after shorter exposures (Fig. 5B & 5C).
DISCUSSION
This study shows that circulating exosomes from human subjects with OHS or from mice
exposed to IH/SF promote reduced insulin sensitivity in naïve adipocytes in vitro, that
responds favorably to CPAP treatment, particularly after long-term adherent therapy, and
such beneficial effects of CPAP are undetectable among OSA patients who opted not to
receive any treatment. Furthermore, plasma exosomes from OHS increased the
differentiation of pre-adipocytes but did not affect their proliferative rates, and also
enhanced adipocyte lipolysis. Experiments in mice exposed for variable durations of either
SF or IH further indicated that short-term exposures do not appear to alter the functional
properties of exosomes, while the findings in exosomes derived from plasma of mice
exposed to longer exposures closely recapitulated the results in OHS patients.
Before we discuss in more detail the potential implications of our findings, we would like to
comment on the reduced insulin sensitivity elicited by plasma exosomes originating from
both SF- and IH-exposed mice. We have previously shown that mice exposed to long-term
SF develop increased body weight and adipose tissue mass, along with mobilization and
differentiation of adipocyte precursors, and adipose tissue inflammation 35, 44, 46, 47. This is
in contrast with mice exposed to chronic IH who display reductions in body weight, along
with increased visceral fat inflammation 48–52, yet these two paradigms are associated with
metabolic dysfunction and insulin resistance, suggesting that in the context of OSA, body
weight may potentiate the effects of obesity, but is not the sole contributor to metabolic
dysfunction. Here however, we explored the isolated effects of circulating exosomes on
naïve adipocytes, such that all of the direct effects of either IH or SF on adipose tissue cells
were essentially precluded by the experimental design, and therefore enabled parallel
comparisons between the functional effects of exosomes in OHS to those of the murine
models of OSA. We should also remark that we characterized plasma exosomes from human
subjects with OHS as well as from both murine OSA models, which are consistently
enriched for tetraspanins, and are often used as exosome biomarkers 53.
Although the majority of patients with OHS have concomitant severe OSA, nocturnal
hypoventilation may be the only respiratory sleep disorder present 6. Moreover, in the
largest clinical trial of OHS to date, 73% of the OHS patients suffered from severe OSA 54.
It is now quite well established that OSA is independently associated with the presence of
metabolic dysfunction in general, and more particularly with the presence of insulin
resistance and dyslipidemia 50, 55, 56. Here we examined different biological markers for
insulin resistance in OHS patients, and also evaluated circulating levels of adiponectin,
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which are low in patients with obesity or type-2 diabetes 57, 58, and correlate with indices of
insulin sensitivity. We found that adiponectin levels were decreased in OHS, and increased
following adherent CPAP treatment in the absence of significant changes in BMI after
treatment.
Elevated plasma RBP4 levels have been associated with the clustering of components of the
metabolic syndrome in insulin-resistant subjects, and in population-based studies 59. Plasma
levels of RBP4 were higher in OHS patients, and were significantly improved with CPAP
intervention over time, but did not change in those patients with OSA who were not
receiving CPAP treatment. These findings provide initial evidence on the favorable impact
of adherent CPAP treatment on metabolic markers in OHS.
Our findings also indicate that exosomes derived from OHS subjects at diagnosis induce
insulin resistance in naïve adipocytes compared to exosomes from the same subjects
following adherent CPAP treatment, particularly when the latter intervention is implemented
for long periods of time (i.e., T-12M or T-24M). Such improvements were conspicuously
absent in untreated OSA patients. In parallel studies, using murine circulating exosomes
from both mid-term and long-term, but not short-term sleep fragmentation (SF) and
intermittent hypoxia (IH), similar responses indicating insulin resistance emerged in murine
adipocytes. Thus, the current findings suggest that chronic perturbations of sleep continuity
or episodic hypoxia lead to altered composition of circulating exosomes, which turn alter the
functional properties of target cells, i.e., adipocytes, to promote the presence of insulin
resistance. Since, exosomes can be released by many cell types and are loaded with a variety
of proteins, lipids, and nucleic acids (including miRNAs) 60, exploration of the potential
dominant cells from which the exosomes originate to alter adipocyte insulin sensitivity is
clearly beyond the scope of the present work, but certainly merits future exploration to better
delineate the specific source cells and cargo elements that foster targeted disruption of
insulin receptor signaling.
Current experiments illustrate for the first time that plasma exosomes of both OHS patients
and from mice exposed to murine models of OSA promote the differentiation of pre-
adipocytes, albeit without altering their proliferative properties, and also induce significant
lipolysis. We have previously shown that chronic SF was associated with substantial
increases in pre-adipocyte differentiation 35, and that such events required activation and
propagation of oxidative stress via NADPH oxidase activity. Additional studies indicated
that IH favors the induction of lipolysis, which in turn adversely affects insulin sensitivity
61–63, and CPAP withdrawal in patients with OSA leads to major increases in circulating
free fatty acids, facilitating metabolic dysfunction 64. Taken together, circulating exosomes
in the context of OHS or murine OSA may provide an inter-cellular communication vehicle
that ultimately disrupts adipocyte homeostasis, resulting in altered metabolic function. It
remains unclear whether exosomes derived from patients with OSA will also modify the
function of other important metabolic cellular targets, such as hepatocytes, myocytes or
pancreatic β cells.
Several studies have examined circulating exosomes in humans with obesity, metabolic
syndrome, and diabetes 22. Severe obesity increases circulating exosomes independent of the
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metabolic syndrome 65, while in two recent studies ob/ob null mice displayed elevated
numbers of exosomes compared to wild-type mice 66, and exosomes bearing cystatin C were
positively associated with metabolic complications of obesity in patients with clinical
vascular diseases 31. Several other studies have isolated exosomes that exhibit biological
activity from the cell culture supernatants in a variety of settings 18, 19, 21. For example,
exosomes isolated from the supernatants of visceral adipose tissue cultures showed that
injection of exosomes derived from diet-induced or genetically obese mice into wild-type
lean mice results in macrophage activation and insulin resistance 32. In addition, isolated
exosomes from the supernatants of differentiated 3T3-L1 cells under hypoxic conditions are
increased in number and also enriched in enzymes related to lipogenesis and promote lipid
accumulation in recipient 3T3-L1 adipocytes 67. Exosomes have also been implicated in the
regulation of energy metabolism and are effectively involved in the communication between
adipocytes 68.
This study provides a compelling proof of concept illustrating that exosomes derived from
OHS patients following CPAP treatment improved insulin sensitivity in naïve human
adipocytes, while absence of any therapeutic intervention, which would be unethical in OHS
but is deemed acceptable in the less severe OSA cases illustrates the absence of any
temporal changes in the functional properties of circulating exosomes. In addition, OHS is a
clinical entity characterized by the coexistence of obesity and hypoxia and hypercapnia
during wakefulness, with a recent study reporting that hypercapnia promotes adipogenesis in
human adipocytes 69. Accordingly, the beneficial effects of CPAP in our OHS cohort could
have resulted from the improvements in both hypoxia and hypercapnia, and therefore future
murine studies may need to explore both the isolated and combined role of hypercapnia to
exosome biological properties in adipocytes. 69 There are several additional limitations in
this study that merit discussion. First, the untreated OSA group is not entirely comparable to
the OHS group, i.e., lower BMI, lower glucose and insulin levels, and slightly higher
adiponectin than OHS at baseline. Nevertheless, as indicated above the ethical issues
involved in purposefully withholding therapy from OHS, prompted us to at least show that
no treatment in OSA resulted on significant changes over time. Second, we used lean mice
on a normal chow diet and exposed them to IH and SF. This strategy was aimed to avoid
additional effects of obesity and dietary components on the experiments, and enable specific
evaluation of the effects of the experimental interventions. Future studies centered around
the impact on exosomal content and function of genetic or dietary obesity, dietary
constitutive components (e.g., fat or carbohydrate content) or physical activity should be
forthcoming70, 71.
As discussed above, plasma-derived exosomes in OHS patients and in mice exposed to OSA
experimental models mediate at least in part the adverse metabolic effects of these
conditions as illustrated by adipocyte-based functional reporter assays. Furthermore, our
results illustrate an important observation, whereby there appear to be continued
improvements in metabolic dysfunction over time with adherent CPAP treatment that are
both apparent in systemic metabolic function (Table 1), and are also illustrated by the
functional properties of circulating exosomes on naïve adipocyte reporter assays. Thus, large
clinical studies to further investigate the utility of monitoring circulating exosomes and their
cargo elements as biomarkers of OHS patients and metabolic health may be an important
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and potentially useful approach to uncover not only the effect of treatment adherence or lack
thereof, but also to identify putative therapeutic targets.
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Uptake of fluorescently labelled exosomes by differentiated human adipocytes cells.
Confocal microscope images illustrating exosome uptake into human adipocytes cells.
Exosomes were isolated from plasma of subjects with obesity hypoventilation and labeled
with the PKH67 Green Fluorescent (lipophilic), Exo-Red (fluorescently-label isolated
exosome RNAs), and Exo-Green (fluorescently-label isolated exosome protein). Panel (A) is
a representative images of human differentiated adipocytes cells were grown on coverslips
for 24 h and the labeled exosomes with PKH67 were added to the cells for 6 h at 37°C.
Panel (B) a representative images of human differentiated adipocytes and the labeled
exosomes with Exo-Red were added to the cells for 6 h at 37°C. Panel (C) is a representative
images of human differentiated adipocytes and the labeled exosomes with Exo-Green were
added to the cells for 6 h at 37°C. Cells were washed and stained with nuclei (blue) stained
with DAPI, n=6, scale bar in 10 μm. As controls, no exosomes were used but PKH67 was
added. The differential interference contrast (DIC) was used to visual the morphology of the
cells without fluorescence.
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Effects of exosomes derived from human subjects, adherent, (Pre- and-Post CPAP
treatments), non-adherent on naïve human adipocytes, exosomes derived from mice exposed
to sleep fragmentation (SF) or intermittent hypoxia (IH), respectively, using a time course of
1 day, 1 week, 2 weeks, 6 weeks and 20 weeks and sleep control (CTL) on a murine naïve
adipocytes for insulin sensitivity. Panel (A) shows the average of pAKT/tAKT ratio of
human exosomes derived from human (Pre- and Post-CPAP (T-2M, T-12M, and T-24M) on
human adipocytes, n=24 per conditions. Panel (B) shows the average of pAKT/tAKT ratio
of SF and CTL exosomes derived from SF time course on murine adipocytes (3T3-L1), n=8
per conditions. Panel (C) shows the average of pAKT/tAKT ratio of IH and RA exosomes
derived from IH time course on murine adipocytes (3T3-L1), n=8 per conditions. * Indicates
statistical significance, p≤ 0.05.
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Effects of exosomes derived from human subjects, adherent, (Pre- and-Post CPAP
treatments), non-adherent on naïve human adipocytes, exosomes derived from mice exposed
to sleep fragmentation (SF), or intermittent hypoxia (IH), respectively, using a time course
of 1 day, 1 week, 2 weeks, 6 weeks and 20 weeks and sleep control (CTL) on naïve
adipocytes for proliferation of pre-adipocytes. Panel (A) shows the average of proliferation
values of human pre-and post-treatments (Pre- and Post-CPAP (T-2M, T-12M, and T-24M),
n=24 per conditions. Panel (B) shows the average of proliferation values of SF and CTL
(3T3-L1), n=8 per conditions. Panel (C) shows the average of proliferation values of IH and
RA, (3T3-L1), n=8 per conditions. * Indicates statistical significance, p≤ 0.05.
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Effects of exosomes derived from human subjects, adherent, (Pre- and-Post CPAP
treatments), non-adherent on naïve human adipocytes, exosomes derived from mice exposed
to sleep fragmentation (SF), or intermittent hypoxia (IH), respectively, using a time course
of 1 day, 1 week, 2 weeks, 6 weeks and 20 weeks and sleep control (CTL) on naïve
adipocytes for differentiation of adipocytes. Panel (A) shows the average of lipids released
values when incubating exosomes derived from human pre-and post-treatments (Pre- and
Post-CPAP (T-2M, T-12M, and T-24M) to differentiated adipocytes on human adipocytes,
n=24 per conditions. Panel (B) shows the average of lipids released values when incubating
exosomes derived from SF or CTL to differentiated adipocyte (3T3-L1), n=8 per conditions.
Panel (C) shows the average of lipids released values when incubating exosomes derived
from IH and RA to differentiated adipocytes (3T3-L1), n=8 per conditions. * Indicates
statistical significance, p≤ 0.05.
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Effects of exosomes derived from human subjects, adherent, (Pre- and-Post CPAP
treatments), non-adherent on naïve adipocytes, exosomes derived from mice exposed to
sleep fragmentation (SF), or intermittent hypoxia (IH), respectively, using a time course of 1
day, 1 week, 2 weeks, 6 weeks and 20 weeks and sleep control (CTL) on naïve adipocytes
for lipolysis. Panel (A) the average of glycerol released when incubating exosomes derived
from human subject pre-and post-CPAP treatments (Pre- and Post-CPAP (T-2M, T-12M,
and T-24M) to differentiated adipocytes on human adipocytes, n=24 per conditions for
lipolysis. Panel (B) shows the average of lipids released values when incubating exosomes
derived from SF or CTL to differentiated adipocytes (3T3-L1). Panel (C) shows the average
of glycerol released when incubating exosomes derived from SF or CTL to differentiated
adipocytes (3T3-L1). * Indicates statistical significance, p≤ 0.05.
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